Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism

References

• GatterllariMWorthingtonJZwarNBarriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physiciansStroke20083922723018048861
   PubMed Web of Science ®Google Scholar
• Pradaxa (dabigatran etexilate mesylate) capsules [prescribing information]Ridgefield, CTBoehringer Ingelheim Pharmaceuticals, Inc2015
   Google Scholar
• Eliquis (apixaban) tablets [prescribing information]Princeton NJBristol-Myers Squibb Company2015
   Google Scholar
• Savaysa (edoxaban) tablets [prescribing information]Parsippany, NJDaiichi Sankyo, Inc2015
   Google Scholar
• Xarelto (rivaroxaban) tablets [prescribing information]Titusville, NJJanssen Pharmaceuticals, Inc2015
   Google Scholar
• ZafarMUVorchheimerDAGaztanagaJAntithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamberThromb Haemost200798488388817938815
   PubMed Web of Science ®Google Scholar
• FurugohriTIsobeKHondaYDU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profilesJ Thromb Haemost2008691542154918624979
   PubMed Web of Science ®Google Scholar
• OgataKMendell-HararyJTachibanaMClinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteersJ Clin Pharmacol201050774375320081065
   PubMed Web of Science ®Google Scholar
• YinOQTetsuyaKMillerREdoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillationEur J Clin Pharmacol201470111339135125168620
   PubMed Web of Science ®Google Scholar
• MatsushimaNLeeFSatoTWeissDMendellJBioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjectsClin Pharm Drug Dev20132358366
   PubMed Web of Science ®Google Scholar
• MendellJTachibanaMShiMKunitadaSEffects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteersJ Clin Pharmacol201151568769420534818
   PubMed Web of Science ®Google Scholar
• BathalaMSMasumotoHOgumaTHeLLowrieCMendellJPharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humansDrug Metab Dispos201240122250225522936313
   PubMed Web of Science ®Google Scholar
• MendellJLeeFChenSWorlandVShiMSamamaMMThe effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitorJ Cardiovasc Pharmacol201362221222123615159
   PubMed Web of Science ®Google Scholar
• MendellJZahirHMatsushimaNDrug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitorAm J Cardiovasc Drugs201313533134223784266
   PubMed Web of Science ®Google Scholar
• MendellJNoveckRJShiMPharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combinationJ Cardiovasc Pharmacol201260433534123064240
   PubMed Web of Science ®Google Scholar
• MendellJBasavapathruniRSwearingenDDravesAZhangGMorganrothJA thorough electrocardiogram study of edoxaban, a novel factor Xa inhibitorJ Clin Pharmacol20115181241124621209229
   PubMed Web of Science ®Google Scholar
• SalazarDEMendellJKastrissiosHModelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillationThromb Haemost2012107592593622398655
   PubMed Web of Science ®Google Scholar
• FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory CommitteeENGAGE AF-TIMI 482014 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/Committees-MeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM420704.pdfAccessed March 7, 2016
   Google Scholar
• YamashitaTKoretsuneYYasakaMRandomized, multicenter, warfarin controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillationCirc J20127681840184722664798
   PubMed Web of Science ®Google Scholar
• WhiteRHThe epidemiology of venous thromboembolismCirculation2003107Suppl 1I-4I-812814979
   PubMed Web of Science ®Google Scholar
• KearonCAklEAComerotaAJAntithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest2012141Supple419Se494S22315268
   PubMed Web of Science ®Google Scholar
• DouketisJDFosterGACrowtherMAPrinsMHGinsbergJSClinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapyArch Intern Med20001603431343611112236
   PubMed Web of Science ®Google Scholar
• LinkinsLAChoiPTDouketisJDClinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysisAnn Intern Med200313989390014644891
   PubMed Web of Science ®Google Scholar
• Hokusai-VTE InvestigatorsBüllerHRDécoususHEdoxaban versus warfarin for the treatment of symptomatic venous thromboembolismN Engl J Med20133691406141523991658
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKDabigatran versus warfarin in the treatment of acute venous thromboembolismN Engl J Med20093612342235219966341
   PubMed Web of Science ®Google Scholar
• EINSTEIN InvestigatorsBauersachsRBerkowitzSDOral rivaroxaban for symptomatic venous thromboembolismN Engl J Med20103632499251021128814
   PubMed Web of Science ®Google Scholar
• EINSTEIN-PE InvestigatorsBüllerHRPrinsMHOral rivaroxaban for the treatment of symptomatic pulmonary embolismN Engl J Med20123661287129722449293
   PubMed Web of Science ®Google Scholar
• AgnelliGBüllerHRCohenAOral apixaban for the treatment of acute venous thromboembolismN Engl J Med201336979980823808982
   PubMed Web of Science ®Google Scholar
• Van der HulleTKooimanJden ExterPLDekkersOMKlokFAHuismanMVEffectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysisJ Thromb Haemost20141232032824330006
   PubMed Web of Science ®Google Scholar
• ColillaSCrowAPetkunWSingerDESimonTLiuXEstimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult populationAm J Cardiol20131121142114723831166
   PubMed Web of Science ®Google Scholar
• Birman-DeychERadfordMJNilasenaDSGageBFUse and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillationStoke20063710701074
   PubMed Web of Science ®Google Scholar
• JanuaryCTWannLSAlpertJS2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm SocietyCirculation20141302071210424682348
   PubMed Web of Science ®Google Scholar
• GageBFWatermanADShannonWBoechlerMRichMWRadfordMJValidation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial FibrillationJAMA20012852864287011401607
   PubMed Web of Science ®Google Scholar
• GiuglianoRRuffCTBraunwaldEEdoxaban versus warfarin in patients with atrial fibrillationN Engl J Med20133692093210424251359
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcmurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• RuffCTGiuglianoRPBraunwaldEComparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsLancet201438395596224315724
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin2014 Available from: www.fda.gov/Drugs/DrugSafety/ucm396470.htmAccessed November 19, 2015
   Google Scholar
• GoldAMCrowtherMLevyGANNEXA-R: a phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of rivaroxaban-induced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (FXA) inhibitorsJ Am Coll Cardiol20156510S
   Web of Science ®Google Scholar
• SiegalDMCurnutteJTConnollySJAndexanet alfa for the reversal of factor Xa inhibitor activityN Engl J Med2015373252413242426559317
   PubMed Web of Science ®Google Scholar
• AnsellJEBakhruSHLaulichtBEUse of PER977 to reverse the anticoagulant effect of edoxabanN Engl J Med2014371222141214225371966
   PubMed Web of Science ®Google Scholar
• ParasrampuriaDAMarburyTMatsushimaNPharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysisThromb Haemost2015113471972725566930
   PubMed Web of Science ®Google Scholar
• ZahirHBrownKSVandellAGEdoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrateCirculation2015131829025403645
   PubMed Web of Science ®Google Scholar